Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - hartkapseln - encorafenibum 50 mg, excipiens pro kapsel. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - encorafenibum - hartkapseln - encorafenibum 75 mg, excipiens pro kapsel. - melanom mit braf-v600-mutation in kombination mit binimetinib,; metastasiertes kolorektalkarzinom (crc) mit einer braf-v600e-mutation in kombination mit cetuximab - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - binimetinibum - filmtabletten - binimetinibum 15 mg, excipiens pro compresso obducto. - melanom mit braf-v600-mutation in kombination mit encorafenib - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - brustgeschwulste - antineoplastische mittel - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Europäische Union - Deutsch - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastische mittel - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - pazopanibhydrochlorid - filmtablette - 200 mg - teil 1 - filmtablette; pazopanibhydrochlorid (36553) 216,7 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aliud pharma gmbh (3270510) - pazopanibhydrochlorid - filmtablette - 400 mg - teil 1 - filmtablette; pazopanibhydrochlorid (36553) 433,4 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm gmbh (3364435) - pazopanibhydrochlorid - filmtablette - 200 mg - teil 1 - filmtablette; pazopanibhydrochlorid (36553) 216,7 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm gmbh (3364435) - pazopanibhydrochlorid - filmtablette - 400 mg - teil 1 - filmtablette; pazopanibhydrochlorid (36553) 433,4 milligramm

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - vedolizumabum - pulver für ein konzentrat zur herstellung einer infusionslösung - praeparatio cryodesiccata: vedolizumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, pro vitro. - colitis ulcerosa, morbus crohn, pouchitis - biotechnologika